aTyr Pharma, Inc.ATYRNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank97
3Y CAGR+2.8%
5Y CAGR+13.1%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
+2.8%/yr
vs +135.6%/yr prior
5Y CAGR
+13.1%/yr
Recent deceleration
Acceleration
-132.8pp
Decelerating
Percentile
P97
Near historical high
vs 5Y Ago
1.9x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 44.68% |
| Q3 2025 | -31.66% |
| Q2 2025 | -28.78% |
| Q1 2025 | 0.30% |
| Q4 2024 | 12.80% |
| Q3 2024 | -4.78% |
| Q2 2024 | -4.08% |
| Q1 2024 | -4.24% |
| Q4 2023 | -26.51% |
| Q3 2023 | 6.96% |
| Q2 2023 | -6.03% |
| Q1 2023 | -60.84% |
| Q4 2022 | 41.08% |
| Q3 2022 | -7.22% |
| Q2 2022 | -1.66% |
| Q1 2022 | -43.26% |
| Q4 2021 | -11.80% |
| Q3 2021 | 26.01% |
| Q2 2021 | -45.03% |
| Q1 2021 | -45.79% |
| Q4 2020 | 24.14% |
| Q3 2020 | -3.07% |
| Q2 2020 | -439.86% |
| Q1 2020 | 131.18% |
| Q4 2019 | -8.44% |
| Q3 2019 | 2.54% |
| Q2 2019 | 4.02% |
| Q1 2019 | 1.44% |
| Q4 2018 | 10.69% |
| Q3 2018 | 32.96% |
| Q2 2018 | 2.54% |
| Q1 2018 | 8.75% |
| Q4 2017 | -3.45% |
| Q3 2017 | 9.07% |
| Q2 2017 | 9.87% |
| Q1 2017 | -5.46% |
| Q4 2016 | 9.65% |
| Q3 2016 | 10.16% |
| Q2 2016 | 4.23% |
| Q1 2016 | 2.23% |